Analysis of clinical characteristics and risk factors of lung cancer complicated with venous thromboembo-lism
Objective To summarize,compare and analyze the clinical process of patients with lung cancer complicated with venous thromboembolism(VTE)to provide the basis for clinical diagnosis.Methods Clinical data of lung cancer patients admitted to our hospital from January 2017 to December 2023 were selected.63 patients with lung cancer complicated with VTE were screened out(VTE group),and 63 patients with lung cancer admitted at the same time(non-VTE group)were selected.Gender,age,body mass index,comorbidities,time of diagnosis of lung cancer,clinical stage of lung cancer,type of lung cancer,treatment,and laboratory tumor marker data of the two groups were compared and analyzed.The clinical characteristics and risk factors of lung cancer complicated with VTE were further analyzed.Results The incidence of age,diabetes and TNM Stage Ⅲ/Ⅳ in VTE group was significantly higher than that in non-VTE group,the difference was significant[(67.23±8.39)years vs 60.21±7.28)years,39.7%vs 15.9%,69.8%vs 47.6%,P<0.05 or P<0.01].The incidence of dyspnea,palpitation and limb pain and swelling in lung cancer patients with VTE was higher than that in lung cancer patients(58.7%vs 36.5%,55.6%vs 28.6%,60.3%vs 0,P<0.05).Laboratory tests of fibrinogen,total cholesterol,low density lipoprotein,ferritin and D-dimer were sig-nificantly better than lung cancer patients(P<0.05 or P<0.01).The incidence of pulmonary embolism and deep VTE was 27.0%vs 73.0%,respectively(P<0.05).Logistic regression analysis showed that the risk of VTE in patients with Ⅲ/Ⅳ lung cancer was higher than that in patients with stage Ⅰ/Ⅱ lung cancer(P<0.05).Increased D-dimer was a risk factor for VTE in lung cancer patients(P<0.01).Conclusion VTE is more likely to occur in lung cancer patients,and it is more likely to occur in old age and diabetes melli-tus.Stage Ⅲ/Ⅳ lung cancer and D-dimer increase are independent risk factors for VTE in lung cancer patients.It suggests that we should pay more attention to the prevention and treatment of thrombus in patients with the above risk factors.